Ann: Second Quarter Results Presentation, page-7

Hi all,

For me this was the most impactful slide in the presentation.

It shows - in inarguable hard cold statistical terms that everyone can understand - that MSB's treatment with Ryoncil is likely to provide in QALY terms 3 more years of a child's life than any other therapy that may qualify as BAT or a component of BAT. We can give paediatric patients today as good a chance of surviving 4 years or more than any other therapy can give for, at most, 1 year.

What is that worth to the US healthcare budget, to the FDA in terms of refocussing scarce administrative resources.....oh, and to every parent in the world.

Now think what that chance is worth to the only person that counts. The child. There is no benefit/ risk analysis that has been put before the FDA that manages to even compare, IMO. Great slide. Good to see MSB getting the point across.



Cheers to all LTSHs.